Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dex ICE for refractory or recurrent lymphoblastic lymphoma
jRCTs041180184Phase 2Active, not recruiting
- Sponsor
- Ministry of Health, Labour and Welfare
- Start
- Dec 2015
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of dexamethasone, ifosfamide, carboplatin and etoposide in lymphoblastic lymphoma (LL), sponsored by Ministry of Health, Labour and Welfare. Primary endpoint: Response rate of Dex ICE chemotherapy. Started Dec 2015; status: active, not recruiting.
02
Drugs
dexamethasoneifosfamidecarboplatinetoposide
03
Conditions
lymphoblastic lymphoma (LL)
Beyond the preview
Go deeper on jRCTs041180184.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs041180184.